 Kymera Therapeutics Inc NASDAQ: KYMR has announced new preclinical data on its IRAKIMiD degrader KT-413s potential as both a monotherapy and in combination with other anticancer agents. The data were featured at the Annual International Conference on Malignant Lymphoma ICML virtual meeting. 